Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon‐Like Peptide‐1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis
Authors:
- 21 September 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11689-11701
Abstract
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for Type 2 diabetes (T2DM) and obesity, but emerging evidence links them to nonarteritic anterior ischemic optic neuropathy (NAION). Whether this risk differs across agents and the underlying mechanisms remains unclear. We aimed to compare the risks of NAION associated with different GLP‐1RAs and to explore the potential molecular mechanisms underlying this adverse reaction. Materials and Methods: A network meta‐analysis was performed to quantitatively compare the differences in NAION risk. Real‐world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) were used for validation. Network toxicology was further applied to identify central hub targets and signalling pathways. Molecular docking was conducted to evaluate the binding capacity of GLP‐1RAs to central hub targets. Results: The network meta‐analysis revealed significant differences in NAION risk across GLP‐1RAs. Compared with non‐GLP‐1RA treatments, semaglutide showed the highest risk (HR = 1.538, 95% CI: 1.305–1.816), followed by liraglutide (HR = 1.251, 95% CI: 1.080–1.450). FAERS pharmacovigilance analysis suggested a strong disproportionate signal for semaglutide (ROR = 94.534, 95% CI: 83.093–107.552) and a statistically significant but weaker signal for liraglutide (ROR = 4.519, 95% CI: 2.617–7.802). Network toxicology identified CASP3 as the central hub target, and pathway enrichment analysis revealed that the underlying mechanisms were primarily related to Alzheimer's disease, neurodegeneration pathways, and lipid and atherosclerosis pathways. Molecular docking suggested that semaglutide and liraglutide had high binding affinity to CASP3. Conclusions: The combined strategy of network meta‐analysis, pharmacovigilance, network toxicology and molecular docking provides insights into possible risk differences and potential mechanisms, and may guide future research on the safety profile of GLP‐1RAs.Keywords
This publication has 30 references indexed in Scilit:
- Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP ‐1 Receptor AgonistsAnnals of Clinical and Translational Neurology, 2026
- New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 DiabetesJAMA Ophthalmology, 2026
- GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 DiabetesJAMA Network Open, 2025
- GLP-1 RAs and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Older Patients With DiabetesJAMA Ophthalmology, 2025
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 CountriesAmerican Journal of Ophthalmology, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With DiabetesJAMA Ophthalmology, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyJAMA Ophthalmology, 2025
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Caspase‐3: Structure, function, and biotechnological aspectsBiotechnology and Applied Biochemistry, 2021
- Online Mendelian Inheritance in Man (OMIM®): Victor McKusick's magnum opusAmerican Journal of Medical Genetics Part A, 2021